CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 120 enrolled
Drug / intervention
Hydroxyethyl Starch +1 moredrug
Likely dose
Hydroxyethyl Starch 7.5mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02361736
NCT02361736N/ACompleted
CompareCT.gov

Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients

Yuanyuan Zhang·interventional·Posted Feb 12, 2015·Updated Mar 24, 2016

In Brief

A clinical study evaluating Hydroxyethyl Starch and Lactate Ringers for Total Fluid Volume Increased. Completed, enrolled 120 participants across 1 site.

Detailed Summary

Hydroxyethyl starch (HES) is commonly used as plasma expander during surgery but may be nephrotoxic as seen in studies in patients with sepsis. The investigators hypothesized that the possible nephrotoxicity of 6% HES 130/0.4 could be revealed by measurements of urinary and plasma neutrophil gelatinase-associated lipocalin and interleukin-18 (IL-18) in old patients with normal renal function during orthopaedic surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTotal Fluid Volume Increased
CountriesChina
CollaboratorsTianjin Union Medical Center, Tianjin First Central Hospital

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 12, 2015
Enrollment StartMar 1, 2015
Primary CompletionDec 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.4 years ago

Interventions

Hydroxyethyl Starchdrug

6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery

Lactate Ringersdrug

Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery